Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

Investment Rating - The report recommends focusing on the vocational education company China Oriental Education (00667.HK) due to its strong growth prospects and operational adjustments [12]. Core Insights - The vocational training sector is experiencing an upward trend, driven by an increase in the number of high school graduates who are not entering university, leading to a growing demand for vocational skills training [2][7]. - China Oriental Education has forecasted a significant increase in adjusted net profit for 2025, with a growth rate between 46% and 51%, translating to a profit range of 767 million to 793 million RMB [6][12]. - The company is implementing refined management strategies to enhance operational efficiency, which is expected to result in a gross margin increase of 5.2 percentage points to 56.5% in 2025 [8]. Summary by Sections Market Overview - The education index fell by 3.2% in the week of February 6-12, underperforming the Hang Seng Index by 4.1 percentage points, but has shown a year-to-date increase of 12.86% [5]. Company Updates - China Oriental Education's new training participants are expected to grow by 6% in 2025, contributing to a revenue increase of 12% to 4.61 billion RMB [6][12]. - The company is targeting high school graduates who did not enter university, with a significant increase in the number of such graduates from 119,000 in 2021 to 386,000 in 2024 [7]. Operational Efficiency - The company is focusing on optimizing marketing expenditures and improving school capacity utilization, which is projected to lower the marketing expense ratio by 2.5 percentage points to 21.2% in 2025 [8]. - Management efficiency is also expected to improve, with a projected management expense ratio of 11.2%, down by 1.1 percentage points [8]. Capital Expenditure and Dividends - Capital expenditures are anticipated to decrease by 33.6% to approximately 660 million RMB in 2025, with a high dividend payout ratio expected to yield a dividend yield of 5.6% [9][10]. Investment Recommendations - The report suggests a focus on vocational education companies, particularly China Oriental Education, due to its strong performance forecasts and strategic adjustments to meet the growing demand for vocational training [12].

Investment Rating - The report maintains a "Buy" rating on the overseas education sector, specifically highlighting China Oriental Education as a key investment target [1]. Core Insights - The report indicates a positive outlook for vocational education training, with operational efficiency continuously improving. China Oriental Education is expected to achieve a net profit growth of 46% to 51% in 2025, with adjusted net profit projected between 767 million to 793 million RMB [1][7]. - The vocational training market is anticipated to benefit from an increase in high school graduates who do not enter university, leading to a significant rise in demand for vocational skills training [2][8]. - The company is implementing refined management strategies to enhance operational efficiency, expecting a gross margin increase of 5.2 percentage points to 56.5% in 2025 [3][9]. - Capital expenditures are projected to decline, with a forecast of approximately 660 million RMB in 2025, a decrease of 33.6% year-on-year, while maintaining a high dividend payout ratio [4][10]. Summary by Sections Market Overview - The education index fell by 3.2% in the week of February 6-12, underperforming the Hang Seng Index by 4.1 percentage points. Year-to-date, the education index has risen by 12.86%, outperforming the Hang Seng Index by 9.93 percentage points [6]. Company Updates - China Oriental Education has released a positive profit forecast for 2025, with an expected net profit growth of 46% to 51%, translating to an adjusted net profit of 767 million to 793 million RMB. The company anticipates a 6% increase in new training participants, driving revenue growth to between 12% and 46.1 billion RMB [7][8]. Vocational Training Demand - The vocational training sector is set to experience growth due to a mismatch in university enrollment rates and an increase in high school graduates. The number of high school graduates has risen by 2.6 million from 2021 to 2024, while university enrollment has only increased by 320,000 during the same period [2][8]. Operational Efficiency - The company is expected to continue its lean management approach from 2024, coordinating recruitment across schools to improve capacity utilization. The marketing expense ratio is projected to decrease by 2.5 percentage points to 21.2% in 2025, contributing to a net profit margin increase of 4.4 percentage points to 17.2% [3][9]. Capital Expenditure and Dividends - The company has initiated a vocational education center construction plan, with five out of six centers expected to be completed between 2023 and 2025. The capital expenditure for 2025 is estimated at 660 million RMB, with a high dividend payout ratio suggesting a dividend yield of 5.6% [4][10]. Investment Recommendations - The report recommends focusing on Hong Kong-listed vocational education companies, particularly China Oriental Education, due to its strong growth prospects and operational adjustments aimed at capturing the vocational training demand from high school graduates [13].

| 指数 | 收盘 | | 涨跌（％） | | | --- | --- | --- | --- | --- | | 名称 | （点） | 1 日 | 5 日 | 1 月 | | 上证指数 | 4134 | 0.05 | -0.75 | 1.43 | | 深证综指 | 2709 | 0.51 | -0.21 | 2.2 | 2026 年 02 月 13 日 映恩生物-B（9606.HK）深度：差异化 ADC 技术平台，2026 年催化剂丰富 ◼ 映恩生物是一家以差异化 ADC 技术平台为核心的创新生物药公司。依托自 主研发的四大领先 ADC 技术平台：DITAC、DIBAC、DIMAC 及 DUPAC， 公司已构建覆盖 HER2、HER3、TROP2、B7-H3 等靶点的多款核心 ADC 管线，同时布局双抗 ADC、全新机制载荷 ADC、自免 ADC 等下一代产品， 适应症涵盖乳腺癌、肺癌、前列腺癌等多个瘤种。 ◼ 多款创新管线达成全球授权合作，全面推进 ADC+IO 2.0 联合疗法。 ◼ DB-1311（B7-H3 ADC）适应症覆盖广泛，2026 年多项数据读出。 ◼ 构建创新 2.0 管线，聚焦下一代 ...

Summary of the Conference Call for Yingensheng Bio Company Overview - **Company**: Yingensheng Bio - **Focus**: Development of ADC (Antibody-Drug Conjugate) new drugs - **Core Products**: DB1,303, DB1,305, DB1,311 targeting various cancers including breast cancer and non-squamous non-small cell lung cancer - **Collaborations**: Partnerships with Biotech and Biogen, with total authorized collaboration transactions exceeding $561 billion [2][7] Key Points and Arguments Product Pipeline and Efficacy - **DB1,305**: A dual antibody therapy (PDL1 and VEGFR) shows an objective response rate (ORR) of 53.8% in platinum-resistant ovarian cancer, significantly higher than single-agent therapies, but with a grade 3 or higher adverse event rate of 32.8% [2][3] - **DB1,311**: Targets B7-H3, achieving an ORR of 42.3% in CRPC patients, with a 9-month progression-free survival (PFS) rate of approximately 58%. The prostate cancer market is expected to reach $9 billion by 2032 [2][11] - **DB1,303**: Targets HER2, with a planned launch for endometrial cancer (EC) as the first indication. Expected global risk-adjusted total sales could reach 15 billion RMB by 2035 [2][15][16] Financials and R&D Investment - **R&D Expenses**: Estimated at approximately 837 million RMB for 2024, with around 349 million RMB for the first half of 2025. The company has nearly 3 billion RMB in cash and cash equivalents, supporting high R&D investments [2][8] - **Market Valuation**: Current market cap is around 28-30 billion HKD, with a target market cap of 48 billion HKD, indicating a potential upside of nearly 50% [4][19] Market Potential - **Dual Antibody and ADC Market**: The dual antibody market is projected to reach $250 billion by 2032, while the ADC market is expected to reach $115.1 billion, totaling approximately $250 billion in market space [3][10] - **Future Revenue Projections**: Expected revenues for 2025, 2026, and 2027 are projected at 1.503 billion, 1.657 billion, and 1.76 billion RMB, respectively, with growth rates of 10% and 6% [3][18] Additional Important Insights - **Team Expertise**: The team is composed of highly experienced members, including founder Dr. Zhu Zhongyuan, who has a PhD from the University of Massachusetts Medical School and an MBA from ECB. The team has a strong background in drug development and commercialization [6] - **Globalization and Licensing Progress**: The company has made significant strides in global expansion and licensing, with a total authorized collaboration transaction amount exceeding $561 billion [7] - **Future Directions**: The company plans to focus on core R&D pipelines, including B7-H4 PD-L1 dual antibody and EGFR HER3 dual antibody ADC projects, while exploring autoimmune fields for future ADC drug development [18] This summary encapsulates the key aspects of Yingensheng Bio's conference call, highlighting its product pipeline, financial health, market potential, and strategic direction.

2月10日早盘，港股市场创新药再度活跃，再鼎医药、信达生物、科伦博泰生物、药明生物、映恩 生物等领涨，恒生医药ETF（159892）盘中涨超2%。 消息面来看，信达生物近日宣布与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全 球研发，首付款达3.5亿美元，里程碑付款有望达85亿美元。 东海证券表示，创新药板块靓丽的业绩表现，充分验证了国产创新药商业模式的有效性，医保加持 下的核心产品放量成为业绩增长基础，BD等对外合作则成为业绩增厚的重要抓手。 每日经济新闻 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com （责任编辑：张晓波 ） ...

Investment Rating - The report assigns an "Outperform" rating for the pharmaceutical sector, indicating a positive outlook compared to the broader market [2][4]. Core Insights - The collaboration between Innovent Biologics and Eli Lilly has been upgraded, aiming to create a global innovative ecosystem for drug development in oncology and immunology. This partnership marks their seventh collaboration, enhancing their strategic relationship over more than a decade [2]. - The Chinese government has introduced a high-quality development plan for traditional Chinese medicine (TCM), focusing on improving raw material supply, innovation, and manufacturing capabilities. The plan aims to establish a collaborative development system by 2030, with significant investments in TCM innovation [2]. Summary by Sections Market Performance - The SW Pharmaceutical Biotechnology Index increased by 0.14% during the week of February 2 to February 8, outperforming the CSI 300 Index, which decreased by 1.33%. The Chinese medicine sector saw a notable rise of 2.56% due to new policies, while vaccines and other bioproducts experienced declines [2]. Strategic Collaborations - Innovent Biologics and Eli Lilly's new agreement includes a $350 million upfront payment and potential milestone payments of up to $8.5 billion, along with a tiered sales revenue sharing model for products outside Greater China. This partnership signifies a shift from traditional licensing to deeper integration of technology platforms and R&D systems [2]. Investment Opportunities - The report highlights continued optimism for Chinese innovative drugs entering international markets, particularly in areas such as antibody-drug conjugates (ADCs), dual antibodies, small nucleic acids, and weight-loss medications. Key companies to watch include Innovent Biologics, 3SBio, WuXi AppTec, and others [2].

Core Viewpoint - The Chinese healthcare industry is at a historical turning point, transitioning from "following innovation" to "leading innovation," with the emergence of trillion-dollar companies becoming a tangible future rather than a distant dream [4][5]. Industry Milestones - By the end of 2025, significant milestones include Eli Lilly becoming the first healthcare company with a market value exceeding $1 trillion, the Hong Kong Stock Exchange leading global financing with over $36 billion, and 3SBio's $1.25 billion upfront payment, indicating China's innovative drugs gaining international pricing power [4][5][7]. Transformation of China's Healthcare Industry - China has evolved from being a major pipeline buyer to a core seller in global business development (BD) transactions, now accounting for 20% of the market, particularly in areas like Antibody-Drug Conjugates (ADC) [7]. - Despite this progress, there remains a significant gap in original innovation compared to the U.S., which is a key reason for the shift in national policy towards new drug innovation [7][8]. Investment Directions - **Direction One**: Investing in original innovations based on top Chinese research institutions is expected to yield high returns, despite the high risks associated with crossing the "valley of death" in technology and commercialization [8][10]. - **Direction Two**: Embracing "three no" companies (no revenue, no profit, not listed) with genuine innovative technologies is becoming a core strategy for professional funds, supported by a robust capital market that allows for high valuations [11][13]. - **Direction Three**: The integration of AI in healthcare is evolving from a mere enabling tool to a creator of new entities, with AI expected to play significant roles in clinical diagnosis, drug development, and even home health management [14][16]. - **Direction Four**: A new era of Chinese multinational corporations (MNCs) is anticipated, with several leading healthcare companies expected to surpass a market value of one trillion, leveraging both internal innovation and global acquisitions [17][19]. Future Outlook - The future of the Chinese healthcare industry is characterized by a convergence of policy, capital, technology (especially AI), and market dynamics, creating an environment ripe for investment in original innovations, pure innovation companies, and AI-driven healthcare solutions [19].

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

本月底法定/註冊股本總額： USD 20,000 FF301 第 1 頁 共 10 頁 v 1.2.0 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 映恩生物 (「本公司」) 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 09606 說明 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 200,000,000 USD 0.0001 USD 20,000 增加 / 減少 (-) USD 本月底結存 200,000,000 USD 0.0001 USD 20,000 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如 ...